GLO1 and myasthenia gravis: The rationale for intervention with Glo1 inducer is to correct a pathogenesis-associated decline in Glo1 expression and/or an increase in the formation of MG, leading to, typically, a 2–3-fold increase in plasma and tissue-specific increase in the concentration of MG [1,7,28].